Halozyme scores $30M in cash for its latest alliance; Bernie Sanders takes aim at $375,000 rare disease drug
→ Now it’s argenx’s turn to sign up on a collaboration deal with Halozyme aimed at using their platform tech to create subcutaneous versions of their therapies. Halozyme is getting $30 million upfront for 3 programs, with $160 million per target in milestones on the table. Halozyme has had a long-running alliance with Roche, among others. “By gaining exclusive access to Enhanze technology for our anti-FcRn asset, we also solidify our leadership position in this exciting new space that has the potential to disrupt the way severe autoimmune diseases are treated,” commented Keith Woods, COO of argenx.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
